Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737014 | 0.91 | SIGMAR1 (0.35) | PLA2G1BPLA2G2AKCNH2SIGMAR1CACNA2D1 | |
| SCHEMBL10284380 | 0.87 | SIGMAR1 (0.41) | PLA2G1BPLA2G2AKCNH2SIGMAR1DNM1 | |
| SCHEMBL21016188 | 0.84 | SIGMAR1 (0.42) | KCNH2SIGMAR1CACNA2D1 | |
| SCHEMBL20076614 | 0.83 | PLA2G1B (0.37) | PLA2G1BPLA2G2AKCNH2SIGMAR1DNM1 | |
| SCHEMBL20856568 | 0.81 | TSHR (0.53) | TSHRTHRBGGPS1 | |
| SCHEMBL21549958 | 0.81 | TSHR (0.53) | TSHRTHRBGGPS1 | |
| SCHEMBL8159115 | 0.81 | TSHR (0.53) | TSHRTHRBGGPS1 | |
| SCHEMBL20856453 | 0.81 | TSHR (0.53) | TSHRTHRBGGPS1 | |
| SCHEMBL20856434 | 0.81 | TSHR (0.53) | TSHRTHRBGGPS1 | |
| SCHEMBL20856432 | 0.81 | TSHR (0.53) | TSHRTHRBGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | PLA2G1B 4676/4885PLA2G2A 4850/4885KCNH2 3551/4885 |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | PLA2G1B 4397/4885PLA2G2A 4613/4885KCNH2 3139/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PLA2G1B 4667/4885PLA2G2A 4836/4885KCNH2 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.